BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$13.62
−1.94%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$14.14
From 52W high−24.79%
Volume6.42M
Market cap$2.06B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$14.14
From 52W high
−24.79%
Volume
6.42M
Market cap
$2.06B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
P/E (TTM)
—
RSI (14)
49.1
MomentumView details →
1D Return
−1.94%
YTD Return
+23.80%
SummaryUpdated Jun 1, 2026
Biohaven Ltd. (NASDAQ:BHVN) is a clinical-stage biopharmaceutical company founded in 2022 as a spinoff from the original Biohaven Pharmaceutical Holding Company. The company emerged following Pfizer's acquisition of the original Biohaven's commercial migraine franchise for $11.6 billion, with the remaining pipeline assets and research programs forming the new independent entity. Biohaven focuses on developing innovative therapies for neurological and immunological diseases, positioning itself to address significant unmet medical needs in these therapeutic areas.
Similar companies
Latest newsMore news →
The U.S. FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug trials, pausing new patient enrollment after rodent findings.10d agoBiohaven entered into a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, for up to $795 million.25d ago